Thromboembolic events reported in association with idarucizumab and andexanet alfa: disproportionality analysis of the Food and Drugs Administration Adverse Eventr Resporting System (FAERS) database (Idarucizumab/andexanet alfa & thromboembolism)

First published 24/10/2023

Last updated 02/04/2024

EU PAS number:

EUPAS107330

Study

Ongoing

Documents

Study protocol

Initial protocol

Idarucizumab_andexanet alfa_thromboebolic events_FAERS_v01_ENCEPP

English (937.54 KB - PDF) View document

Updated protocol

Idarucizumab_andexanet alfa_thromboebolic events_FAERS_v01_1_ENCEPP

First published: 22/02/2024

English (940.16 KB - PDF) View document

Study results

Study report

Other information

Secondary tabs